問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳啟豪
下載
2025-04-01 - 2032-12-31
Condition/Disease
Progression-free survival (PFS): Time from randomization to the first recorded disease progression or death from any cause, whichever occurs first. Overall survival (OS): Time from randomization to death from any cause.
Test Drug
Pembrolizumab (MK-3475) Sacituzumab Tirumotecan (MK-2870)
Participate Sites5Sites
Recruiting5Sites
2020-05-01 - 2025-12-31
2026-05-15 - 2028-04-30
Participate Sites2Sites
Recruiting2Sites
2022-05-01 - 2025-05-09
Participate Sites7Sites
Recruiting7Sites
2020-03-01 - 2027-12-31
Participate Sites3Sites
Recruiting3Sites
2019-10-01 - 2046-12-31
Participate Sites12Sites
Recruiting12Sites
2021-12-16 - 2029-12-31
2022-05-01 - 2025-12-31
2021-07-01 - 2025-12-31
Participate Sites4Sites
Recruiting4Sites
2019-02-01 - 2026-12-31
Participate Sites6Sites
Recruiting6Sites
全部
